Scholarlink

Background <p>The increasing prevalence of cognitive impairments (CI), such as Alzheimer's disease and dementia, requires a multidisciplinary approach to prevention. Brief cognitive screening in community pharmacies can help identify CI in early stages, within advanced pharmaceutical care, and effectively reduce the workload of ambulatory care. Study objectives were to assess the association between patients' cognitive ability as determined by standardised cognitive screening and the presence of modifiable Dementia Risk factors, as well as at-risk medication use related to CI within pharmaceutical counselling in community pharmacies.</p> Methods <p>Data collection was realised between 2018 and 2019, retrospective analysis 2024–2025. This study retrospectively analysed data from a clinical cohort study (N = 323). A score expressed cognitive abilities in a short version of the Montreal Cognitive Assessment (s-MoCA), with a cut-off score of ≤ 12 for CI. Dementia risk factors were assessed according to the Cardiovascular Risk Factors, Ageing, and Incidence of Dementia (CAIDE) Risk Score and the cumulative effect of at-risk medications with anticholinergic activity on a person's cognitive function by the Anticholinergic Cognitive Burden Scale (c-ACB).</p> Results <p>Within the provision of pharmaceutical service, 80.50% (N = 260) of respondents were identified with lower cognitive abilities under a normal s-MoCA score. The global mean s-MoCA (± SD) was 9.54 ± 3.38 points. 29.72% (N = 96) of patients had CAIDE 10 + , and 57.59% (N = 186) of patients used at-risk medication (c-ACB 3 +). We found a significant relationship between s-MoCA and CAIDE/c-ACB, respectively (<i>P</i> &lt; 0.001; R = − 0.2013; and <i>P</i> &lt; 0.0001; R = − 0.3961).</p> Conclusions <p>Cognitive screening in community pharmacies can help identify patients with MCI. In addition, evaluation of CAIDE and at-risk medication use can improve advanced pharmaceutical care for patients with a high risk of CI.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Risk of Mild Cognitive Impairment and Its Relation to Anticholinergics Revealed Within Screening in a Community Pharmacy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月8日

查看全文
  • Zuzana Macekova,
  • Nikola Hudakova,
  • Tomas Fazekas,
  • Miroslava Snopkova,
  • Jozef Dragasek,
  • Viera Zufkova,
  • Jan Klimas

摘要

Background

The increasing prevalence of cognitive impairments (CI), such as Alzheimer's disease and dementia, requires a multidisciplinary approach to prevention. Brief cognitive screening in community pharmacies can help identify CI in early stages, within advanced pharmaceutical care, and effectively reduce the workload of ambulatory care. Study objectives were to assess the association between patients' cognitive ability as determined by standardised cognitive screening and the presence of modifiable Dementia Risk factors, as well as at-risk medication use related to CI within pharmaceutical counselling in community pharmacies.

Methods

Data collection was realised between 2018 and 2019, retrospective analysis 2024–2025. This study retrospectively analysed data from a clinical cohort study (N = 323). A score expressed cognitive abilities in a short version of the Montreal Cognitive Assessment (s-MoCA), with a cut-off score of ≤ 12 for CI. Dementia risk factors were assessed according to the Cardiovascular Risk Factors, Ageing, and Incidence of Dementia (CAIDE) Risk Score and the cumulative effect of at-risk medications with anticholinergic activity on a person's cognitive function by the Anticholinergic Cognitive Burden Scale (c-ACB).

Results

Within the provision of pharmaceutical service, 80.50% (N = 260) of respondents were identified with lower cognitive abilities under a normal s-MoCA score. The global mean s-MoCA (± SD) was 9.54 ± 3.38 points. 29.72% (N = 96) of patients had CAIDE 10 + , and 57.59% (N = 186) of patients used at-risk medication (c-ACB 3 +). We found a significant relationship between s-MoCA and CAIDE/c-ACB, respectively (P < 0.001; R = − 0.2013; and P < 0.0001; R = − 0.3961).

Conclusions

Cognitive screening in community pharmacies can help identify patients with MCI. In addition, evaluation of CAIDE and at-risk medication use can improve advanced pharmaceutical care for patients with a high risk of CI.